ASNC is the premier source for education and quality in the rapidly expanding area of cardiac amyloidosis.

Through its initiatives and partnerships, ASNC is supporting a collaborative approach to awareness, early diagnosis, and effective treatments that will save lives and improve the quality of life for patients with cardiac amyloidosis. Access the latest educational resources and activities and share with your colleagues.


New Virtual Program!

Register now for ASNC’s Cardiac Amyloidosis for Community Cardiologists: A Case-Based Approach, a three-part live webinar series taking place on June 9, 17, and 25, 2026.

Cardiac Amyloidosis for Community Cardiologists: A Case-Based ApproachAdvance your expertise in cardiac amyloidosis with this 3-part live webinar series designed specifically for community-based healthcare providers. Get in-depth didactic presentations and case-based discussions on diagnosing, treating, and managing patients with known or suspected cardiac amyloidosis through a multidisciplinary approach.

Each 2-hour session will help you build the skills needed to detect cardiac amyloidosis, implement current and evolving treatments, and ultimately deliver more effective, timely care.

This program is free for ASNC members and only $25 for non-members.

Not yet an ASNC member? Join or renew now.


Special Cardiac Amyloidosis Issue of Imaging Insights

Evolving Diagnostic and Therapeutic Landscape in ATTR-CM

Read Now


OnDemand - Bone Scintigraphy for Cardiac Amyloidosis: A four-lecture series of short videos delivered by ASNC Experts

 

 

 

 

 

 

 

 

Watch Now


Cardiac Amyloidosis Tools

Visit the ASNC Resource Library for a complete listing of our cardiac amyloid tools.

Interpretation and Reporting of Cardiac Scintigraphy with Bone-Avid Tracers in Suspected Transthyretin Cardiac Amyloidosis.

Download these Think Amyloid posters and our pocket guide to distribute to your multidisciplinary care team.


Cardiac Amyloidosis Flowchart

ASNC Members can access the 11"x17" Cardiac Amyloidosis Flowchart and our Transthyretin Cardiac Amyloidosis: Frequently Asked Questions guide.

Download our new 11"x17" flowchart designed to guide your clinical assessment of cardiac amyloidosis.


Transthyretin Cardiac Amyloidosis: Frequently Asked Questions Guide

ASNC Members can download our Transthyretin Cardiac Amyloidosis: Frequently Asked Questions Guide.

 

 

 

 

 

 

 

 


ASNC Issues Statement on How to Use HMDP in Cardiac Amyloidosis Imaging

Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive diagnosis of transthyretin (ATTR) cardiac amyloidosis, should not delay imaging in at-risk patients. Instead, ASNC is guiding imagers to use 99mtechnetium (99mTc)-hydroxymethylene diphosphonate (HMDP or HDP) to ensure patients continue receiving prompt evaluation of, and treatment for, cardiac amyloidosis.

Read Now


Online Activities

Cardiac Amyloidosis: Tc-99m PYP Imaging - How to Do It Right

  • Robert Pagnanelli, BSRT(R)(N), CNMT, NCT, FASNC, Duke Regional Hospital, Durham, NC
  • April Mann, MBA, CNMT, NCT, RT(N), FANC, MASNC, Hartford Hospital, Hartford, CT

This activity is supported by an educational grant from Pfizer.

No CME/CE provided.

View Now


Guidelines


Practice Points

  • 99m Technetium-Pyrophosphate Imaging for Transthyretin Cardiac Amyloidosis - 2019

Publications

Journal of Nuclear Cardiology (JNC)


Partners

Amyloidosis Foundation

 

ASNC is uniquely qualified to provide education, information and advocacy that ensures appropriate referrals for Tc-99m PYP imaging; supports high-quality testing, interpretation and reporting of Tc-99m PYP imaging by imagers; and encourages fair reimbursement of Tc-99m PYP services and approval of CA treatment agents.